Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study

Sarah Watson; Benjamin Verret; Stanislas Ropert; Julien Adam; Rastislav Bahleda; Sylvain Briand; Andrea Cavalcanti; Ali N. Chamseddine; Charles Court; Elie Fadel; Matthieu Faron; Leila Haddag-Miliani; Clémence Henon; Cécile Le Pechoux; Antonin Levy; Olaf Mercier; Carine Ngo; Charles Honoré; Axel Le Cesne; Olivier Mir

doi:10.1002/cam4.5147

Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study

Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag-Miliani, Clémence Henon, Cécile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honoré, Axel Le Cesne, Olivier Mir

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

6 Citations (Scopus)

Résumé

Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single-agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI-CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1–6.5), and median OS was 9.9 months (95%CI: 6.6–13.4). Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.

langue originale	Anglais
Pages (de - à)	3160-3166
Nombre de pages	7
journal	Cancer Medicine
Volume	12
Numéro de publication	3
Les DOIs	https://doi.org/10.1002/cam4.5147
état	Publié - 1 févr. 2023

Accès au document

10.1002/cam4.5147

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Watson, S., Verret, B., Ropert, S., Adam, J., Bahleda, R., Briand, S., Cavalcanti, A., Chamseddine, A. N., Court, C., Fadel, E., Faron, M., Haddag-Miliani, L., Henon, C., Pechoux, C. L., Levy, A., Mercier, O., Ngo, C., Honoré, C., Cesne, A. L., & Mir, O. (2023). Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study. Cancer Medicine, 12(3), 3160-3166. https://doi.org/10.1002/cam4.5147

@article{e18e39ffd44a48599010df8fc198f01d,

title = "Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study",

abstract = "Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single-agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI-CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1–6.5), and median OS was 9.9 months (95%CI: 6.6–13.4). Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.",

keywords = "angiosarcoma, cardiac sarcoma, gemcitabine, sarcoma, soft tissue neoplasms",

author = "Sarah Watson and Benjamin Verret and Stanislas Ropert and Julien Adam and Rastislav Bahleda and Sylvain Briand and Andrea Cavalcanti and Chamseddine, {Ali N.} and Charles Court and Elie Fadel and Matthieu Faron and Leila Haddag-Miliani and Cl{\'e}mence Henon and Pechoux, {C{\'e}cile Le} and Antonin Levy and Olaf Mercier and Carine Ngo and Charles Honor{\'e} and Cesne, {Axel Le} and Olivier Mir",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2023",

month = feb,

day = "1",

doi = "10.1002/cam4.5147",

language = "English",

volume = "12",

pages = "3160--3166",

journal = "Cancer Medicine",

issn = "2045-7634",

number = "3",

}

Watson, S, Verret, B, Ropert, S, Adam, J, Bahleda, R, Briand, S, Cavalcanti, A, Chamseddine, AN, Court, C, Fadel, E, Faron, M, Haddag-Miliani, L, Henon, C, Pechoux, CL, Levy, A, Mercier, O, Ngo, C, Honoré, C, Cesne, AL & Mir, O 2023, 'Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study', Cancer Medicine, VOL. 12, Numéro 3, p. 3160-3166. https://doi.org/10.1002/cam4.5147

TY - JOUR

T1 - Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma

T2 - A multicenter, retrospective study

AU - Watson, Sarah

AU - Verret, Benjamin

AU - Ropert, Stanislas

AU - Adam, Julien

AU - Bahleda, Rastislav

AU - Briand, Sylvain

AU - Cavalcanti, Andrea

AU - Chamseddine, Ali N.

AU - Court, Charles

AU - Fadel, Elie

AU - Faron, Matthieu

AU - Haddag-Miliani, Leila

AU - Henon, Clémence

AU - Pechoux, Cécile Le

AU - Levy, Antonin

AU - Mercier, Olaf

AU - Ngo, Carine

AU - Honoré, Charles

AU - Cesne, Axel Le

AU - Mir, Olivier

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single-agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI-CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1–6.5), and median OS was 9.9 months (95%CI: 6.6–13.4). Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.

AB - Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single-agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI-CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1–6.5), and median OS was 9.9 months (95%CI: 6.6–13.4). Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.

KW - angiosarcoma

KW - cardiac sarcoma

KW - gemcitabine

KW - sarcoma

KW - soft tissue neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85135881275&partnerID=8YFLogxK

U2 - 10.1002/cam4.5147

DO - 10.1002/cam4.5147

M3 - Article

C2 - 35971325

AN - SCOPUS:85135881275

SN - 2045-7634

VL - 12

SP - 3160

EP - 3166

JO - Cancer Medicine

JF - Cancer Medicine

IS - 3

ER -